Neugenica

Oral Mucositis (Radiation Side Effect)

Neugenica develops synthetic polymers for the treatment and prevention of oral mucositis, a common side effect of cancer radiation therapy. These polymers can be used as a stand-alone therapy, or as drug delivery vehicles to the oral cavity.

Approach

Substituted Ether PolymersOral mucositis is a common side effect of cancer patients receiving radiation therapy. It occurs as a result of radiation induced damage to the endothelium lining the upper GI tract. If left untreated, severe oral mucositis can lead to pain and malnutrition and can be fatal. Moreover, this side effect limits administration of higher doses of radiation therapy. Current treatment relies on the usage of anti-inflammatory medications, however these medications have dangerous side effects at the doses required. Neogenica develops substituted ether polymers that have mucoadhesive properties and coat the oral cavity. These polymers can provide pain relief and protect against the development of further mucositis. Moreover, therapeutics can be conjugated to the polymers, allowing them to act as drug delivery vehicles.

Patents

Substituted Cyclic Ether Polymers, and Conjugates and Uses Thereof
Assigned to the University of Iowa Research Foundation

Development Stage

Pre-clinical validation and development

Innovation Opportunity

  • Materials science
  • Drug delivery systems
  • Cancer treatment side effects

Partnering

Neogenica may be interested in industry or academic partnerships to accelerate the preclinical development of its cyclic ether polymers. Neogenica may also be interested in partnering its polymers to be used as a drug delivery system in conjunction with pre-existing therapies.

Contact Information


Claim Your Page
Is this your organization? Submit your contact information below.